A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

por Eisen, T, Loembé, A-B, Shparyk, Y, MacLeod, N, Jones, R J, Mazurkiewicz, M, Temple, G, Dressler, H, Bondarenko, I
Publicado 2015

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepat...

por Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P., Graham, J., Fartoux, L., Deptala, A., Studeny, M., Schnell, D., Hocke, J., Loembé, A-B., Meyer, T.
Publicado 2018